GARFIELD-AF: risk profiles, treatment patterns and 2-year outcomes in patients with atrial fibrillation in Germany, Austria and Switzerland (DACH) compared to 32 countries in other regions worldwide

Selection of Non-vitamin K Antagonist Oral Anticoagulant for Stroke Prevention in Atrial Fibrillation Based on Patient Profile: Perspectives from Vietnamese Experts. Part 2

“…In patients with AF, the prevalence of chronic kidney disease (CKD) was found to be 10.8%. [ 5 ] The prevalence of CKD is known to increase with age. In a study of elderly patients with AF in Vietnam, the rate of abnormal renal function was 22.2%.…”

“…[ 22 ] According to multinational data, the prevalence of diabetes in patients with AF is 22.2%, and this proportion ranges from 15.7% to 44.4% in Vietnam. [ 5 – 7 ] Diabetes is a well-established risk factor for AF through multiple pathomechanisms. [ 23 ] Diabetes increases the risk of all-cause mortality and cardiovascular mortality, as well as reducing the quality of life in patients with AF.…”

Selection of Non-vitamin K Antagonist Oral Anticoagulant for Stroke Prevention in Atrial Fibrillation Based on Patient Profile: Perspectives from Vietnamese Experts. Part 1

“…[ 10 ] Since their introduction, the use of NOACs has become widespread, and this has resulted in improved clinical outcomes, such as ischaemic stroke and mortality rates, in patients with AF. [ 11 , 12 ] In the absence of any contraindications, NOACs are now being considered the preferred first-line treatment for preventing stroke in patients with AF. [ 13 , 14 ] As the era of NOACs draws to a close, the introduction of newer anticoagulants, such as Factor XIa inhibitors, has initiated Phase III trials.…”